Enclomiphene vs testosterone replacement therapy
Every row cites its source. Where a cell reflects our own reading of the evidence rather than an external source, the row says so.
Stimulate your own production, or replace it from outside. The trials that compared them directly are the best data on this site, and both directions carry real tradeoffs.
| Dimension | Enclomiphene | Comparator | Source |
|---|---|---|---|
| Mechanism | Blocks estrogen feedback; LH and FSH rise; testes keep producing | Exogenous hormone; LH and FSH fall by feedback; testicular production shuts down | source |
| Total testosterone achieved | 604 +/- 160 ng/dL (25 mg, week 6); normalized in phase III | 500 +/- 278 ng/dL (gel, week 6); difference not significant | source |
| Sperm production | Maintained in the normal range through 16 weeks of phase III | Marked reduction in spermatogenesis in the same trials; label warns androgens may lead to azoospermia | source |
| Hematocrit | Rose less in pooled program data | Rose more; label requires checks at baseline, 3-6 months, then annually, with dose reduction or stopping for polycythemia | source |
| Approval status | Not approved for anything, anywhere; compounded under interim policy | FDA-approved for classical primary and hypogonadotropic hypogonadism; label states safety and efficacy not established for age-related low testosterone | source |
| Symptom evidence | None: trials measured hormones and semen, not symptoms; EMA refused partly on this gap | Approved on replacement physiology with decades of use; symptomatic benefit in age-related low testosterone remains contested territory per its own label limits | source |
| Fertility guidance | Axis-preserving class; guidelines discuss SERMs among options for men needing fertility | Endocrine Society recommends against starting testosterone in men planning near-term fertility | source |
| Clot risk | EMA cited venous thromboembolism risk in refusing it | VTE warning on the testosterone label | source |
| What you can verify about the product | Compounded: no FDA-reviewed manufacturing; ask the pharmacy for a certificate of analysis | Approved products with labels, lot standards, boxed warnings and pharmacovigilance | source |